The financial world may be in crisis, but top-tier medical device companies can still raise capital. But at what price? Four medical device execs answer those questions and many more.
by Tom Salemi
Numbers don't lie. By all accounts, venture capital commitments to all industries--including medical device companies--over the first quarter of this...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
While the adoption of most favored nation drug pricing in the US stands to affect Japanese biopharma firms now heavily reliant on this market, it might also present an opportunity for pricing and policy reforms at home.
